• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    89Bio Inc (NQ: ETNB )

    8.260 +0.010 (+0.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 653,066
    Open 8.320
    Bid (Size) 7.650 (50)
    Ask (Size) 8.340 (3)
    Prev. Close 8.250
    Today's Range 8.180 - 8.450
    52wk Range 6.575 - 22.93
    Shares Outstanding 75,480,884
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -26.84%
    -26.84%
    1 Month
    -29.04%
    -29.04%
    3 Month
    -22.88%
    -22.88%
    6 Month
    +17.50%
    +17.50%
    1 Year
    -48.31%
    -48.31%

    More News

    Read More
    89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
    From 89bio, Inc.
    Via GlobeNewswire
    Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
    Via The Motley Fool
    89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
    Via Benzinga
    89bio to Participate in the Leerink Partners Global Biopharma Conference
    From 89bio, Inc.
    Via GlobeNewswire
    Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment
    Via Investor's Business Daily
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
    From 89bio, Inc.
    Via GlobeNewswire
    Biotech Stocks Madrigal, Altimmune In A Tizzy As New Weight-Loss Rival Enters The Arena
    Via Investor's Business Daily
    89bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    Liver Disease Player 89Bio Downgraded: Analyst Sees Short-Term Uncertainties In Fatty Liver Drug Development
    Via Benzinga
    89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Announces Closing of its Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From 89bio, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    89bio, Inc. Announces Upsized Pricing of $150.0 Million Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
    From 89bio, Inc.
    Via GlobeNewswire
    89bio Outlines Roadmap For Pivotal Studies For Lead Program In Fatty Liver Disease
    Via Benzinga
    Exposures Product Safety
    89bio Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis (NASH); Program Initiation Planned in the First Half of 2024
    From 89bio, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.